Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. In pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Jerusalem, Guy, Park, Yeon Hee, Yamashita, Toshinari, Hurvitz, Sara A., Modi, Shanu, Andre, Fabrice, Krop, Ian E., Gonzàlez Farré, Xavier, You, Benoit, Saura, Cristina, Kim, Sung-Bae, Osborne, Cynthia R., Murthy, Rashmi K., Gianni, Lorenzo, Takano, Toshimi, Liu, Yali, Cathcart, Jillian, Lee, Caleb, Perrin, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Briefs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716244/
https://www.ncbi.nlm.nih.gov/pubmed/36255231
http://dx.doi.org/10.1158/2159-8290.CD-22-0837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716244/
https://www.ncbi.nlm.nih.gov/pubmed/36255231
http://dx.doi.org/10.1158/2159-8290.CD-22-0837

Ejemplares similares